CCB
VTYX

Cutter & Co Brokerage’s Ventyx Biosciences VTYX Stock Holding History

Cutter & Co Brokerage’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,000
Closed -$62.1K – 171
2025
Q1 		$62.1K Buy
+54,000
New +$92.7K 0.01% 179

Other funds holding VTYX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Cutter & Co Brokerage's VTYX Position: Q2 2025 in Review

Cutter & Co Brokerage sold out of Ventyx Biosciences (VTYX) in Q2 2025, closing a stake of 54,000 shares — an estimated $62.1K sold.

Cutter & Co Brokerage first reported a position in VTYX in Q1 2025 and held it in 1 quarter. The position peaked at $62.1K in Q1 2025. 114 funds tracked by Wall St. Rank hold VTYX as of Q2 2025.

  • Cutter & Co Brokerage reported no remaining Ventyx Biosciences position as of Q2 2025 after selling out during the quarter.
  • Cutter & Co Brokerage sold 54,000 Ventyx Biosciences shares in Q2 2025, an estimated $62.1K.
  • Cutter & Co Brokerage first reported a position in Ventyx Biosciences in Q1 2025 and held it in 1 quarter.
  • Cutter & Co Brokerage's Ventyx Biosciences position peaked at $62.1K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2025.

Based on Cutter & Co Brokerage's 13F filing for Q2 2025.